Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OTLKW

Outlook Therapeutics (OTLKW)

Outlook Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OTLKW
DateTimeSourceHeadlineSymbolCompany
16/09/202422:05GlobeNewswire Inc.Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell SeriesNASDAQ:OTLKWOutlook Therapeutics Inc
13/09/202423:05GlobeNewswire Inc.Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference SeriesNASDAQ:OTLKWOutlook Therapeutics Inc
04/09/202422:35GlobeNewswire Inc.Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical TrialNASDAQ:OTLKWOutlook Therapeutics Inc
03/09/202422:45GlobeNewswire Inc.Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
14/08/202421:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
12/08/202423:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
07/08/202422:35GlobeNewswire Inc.Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and WebcastNASDAQ:OTLKWOutlook Therapeutics Inc
30/07/202423:10GlobeNewswire Inc.Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024NASDAQ:OTLKWOutlook Therapeutics Inc
08/07/202422:35GlobeNewswire Inc.Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
11/06/202423:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Virtual Investor Pitch ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
28/05/202422:05GlobeNewswire Inc.Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
16/05/202407:00GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
13/05/202422:50GlobeNewswire Inc.Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
09/05/202422:45GlobeNewswire Inc.Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and WebcastNASDAQ:OTLKWOutlook Therapeutics Inc
02/05/202423:05GlobeNewswire Inc.Outlook Therapeutics® to Present at the Retina World Congress 2024NASDAQ:OTLKWOutlook Therapeutics Inc
29/04/202423:00GlobeNewswire Inc.Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseNASDAQ:OTLKWOutlook Therapeutics Inc
16/04/202406:15GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionNASDAQ:OTLKWOutlook Therapeutics Inc
22/03/202422:35GlobeNewswire Inc.Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDNASDAQ:OTLKWOutlook Therapeutics Inc
19/03/202408:10GlobeNewswire Inc.Outlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionNASDAQ:OTLKWOutlook Therapeutics Inc
12/03/202423:05GlobeNewswire Inc.Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitNASDAQ:OTLKWOutlook Therapeutics Inc
15/02/202400:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateNASDAQ:OTLKWOutlook Therapeutics Inc
01/02/202400:05GlobeNewswire Inc.Outlook Therapeutics® Doses First Subject in NORSE EIGHTNASDAQ:OTLKWOutlook Therapeutics Inc
24/01/202400:00GlobeNewswire Inc.Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
23/12/202300:05GlobeNewswire Inc.Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EUNASDAQ:OTLKWOutlook Therapeutics Inc
20/12/202300:05GlobeNewswire Inc.Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
07/12/202300:05GlobeNewswire Inc.Outlook Therapeutics® Announces Strategic Organizational RealignmentNASDAQ:OTLKWOutlook Therapeutics Inc
28/11/202300:05GlobeNewswire Inc.Outlook Therapeutics® Announces Receipt of Type A Meeting Minutes and Reiterates Regulatory Path Forward for ONS-5010NASDAQ:OTLKWOutlook Therapeutics Inc
15/11/202300:05GlobeNewswire Inc.Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Head of EuropeNASDAQ:OTLKWOutlook Therapeutics Inc
02/11/202323:05GlobeNewswire Inc.Outlook Therapeutics® Provides Update on Type A Meetings with FDANASDAQ:OTLKWOutlook Therapeutics Inc
01/11/202323:05GlobeNewswire Inc.Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) ConferenceNASDAQ:OTLKWOutlook Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:OTLKW